Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401144 | 1.00 | CASP3 (0.48) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL29402434 | 1.00 | CASP3 (0.48) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL7650015 | 1.00 | CASP3 (0.48) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL29401786 | 0.88 | CASP3 (0.52) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL3070048 | 0.88 | CASP3 (0.52) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL30656017 | 0.88 | CASP3 (0.52) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL29368798 | 0.88 | CASP3 (0.52) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL29692865 | 0.88 | CASP3 (0.47) | CASP3KMT2AEPHX2PIN1 | |
| SCHEMBL5706475 | 0.87 | CASP3 (0.47) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL5706460 | 0.86 | PTPN1 (0.48) | CASP3KMT2AMDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112204050-B | Anti-MS 4A6A antibodies and methods of use thereof | 艾莱克特有限责任公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119431582-A | Anti-TMEM 106B antibodies and methods of use thereof | 艾莱克特有限责任公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-111971301-B | Anti-MS 4A antibodies and methods of use thereof | 艾莱克特有限责任公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-111886246-B | Anti-TMEM 106B antibodies and methods of use thereof | 艾莱克特有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-116981696-A | anti-TMEM 106B antibodies and methods of use thereof | 艾莱克特有限责任公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-107708733-B | Anti-sortilin antibodies and methods of use thereof | 艾利妥 | 2022-11-15 | — | — | CN | disclosed |
| CN-112204050-A | anti-MS 4A6A antibodies and methods of use thereof | 艾莱克特有限责任公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-111971301-A | anti-MS 4A4A antibodies and methods of use thereof | 艾莱克特有限责任公司 | 2020-11-20 | — | — | CN | disclosed |
| CN-111886246-A | anti-TMEM 106B antibodies and methods of use thereof | 艾莱克特有限责任公司 | 2020-11-03 | — | — | CN | disclosed |
| US-7902333-B2 | activated ester of the carboxyl-containing compound (carboxylic acid) is reacted with H217O or H218O in the presence of an activator; labelled amino acid | RIKEN (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902333-B2 | activated ester of the carboxyl-containing compound (carboxylic acid) is reacted with H217O or H218O in the presence of an activator; labelled amino acid | RIKEN (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20080206820-A1 | Labeling Methods with Oxygen Isotopes | RIKEN (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080206820-A1 | Labeling Methods with Oxygen Isotopes | RIKEN (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1757568-A1 | METHOD OF LABELING WITH ISOTOPE OF OXYGEN | Riken (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206820-A1 | Labeling Methods with Oxygen Isotopes | HAO2, CYP2C18, CA7 | CASP3 3249/4885KMT2A 1910/4885EPHX2 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.